

Thursday, 24 May 2018

13.00-13.30	Opening of the EUFEPS 2018 Erem Bilensoy, EUFEPS President, Conference Co_Chair Panos Macheras, EUFEPS Senator, Conference Co-Chair	
13.30-14.00	PL-1 Stefan Knapp, Germany, "Novel Molecular Targets"	
14.00-14.30	PL-2 Mansoor Khan, US "Innovations and Nanomedicines: Balancing Responsible Science with Regulations for Success"	
14.30-15.00	PL-3 Jukka Rantanen, Denmark, "Manufacturing of Personalized Medicines"	
15.00-15.30	Coffee break and Poster Session-1	
Parallel sessions I		
15.30-17.00	Physiology of the GI tract relevant for drug absorption	Nanomedicines and nanosimilars: How to assess how similar? <i>Organized by EUFEPS Nanomedicine Network</i>
15.30-16.00	IL-1 Patrick Augustijns, Belgium "Intestinal drug absorption: What do we know and what should we understand better?"	IL-4 Gerrit Borchard, Switzerland "Bench to Mensch and back: Identifying critical quality attributes for nanomedicines"
16.00-16.30	IL-2 Martin Brandl, Denmark "Colloidal structures and drug absorption: from amorphous nanoparticles to bile salt micelles"	IL-5 Beatriz Silva Lima, Portugal "Regulator's point of view for nanomedicines and nanosimilars"
16.30-17.00	IL-3 Panos Macheras, Greece "Do we need to consider a reaction limited in Vivo drug dissolution model?"	OP-1 Beat Flühmann, Switzerland "What is the cost of lacking regulatory clarity for nanosimilars?" OP-2 Stefan Mühlebach, Switzerland "Complex drugs: Challenges in selecting nanomedicines and their follow-on versions for a drug formulary"
17.00-18.15	Flash oral presentations <p style="text-align: center;"> FP-1 Daniel Sironi, Denmark "Assessing the performance of an amorphous solid dispersions with the novel dissolution/permeation setup Permaloop" FP-2 Ardita Veseli, Slovenia "Simple thermodynamic BSC solubility with 5 mg tested compound" FP-3, Emre Şefik Çağlar, Turkey "Preparation, optimization and in vitro-in vivo evaluation of voriconazole loaded topical mats of Poly(lactic acid)/Poly(ethylene succinate) blends for skin infections" FP-4 Eireini Christodoulou, Greece "Serum and tissue pharmacokinetics of saffron aqueous extract after i.v. and peros administration to C5/BL6J mice" FP-5 Diego Perinelli, Italy "In vitro and in vivo investigation of N-acyl amino based surfactants as permeability enhancers" FP-6 Nazlı Erdoğan, Turkey "Novel anionic and cationic polymeric nanocapsules for oral delivery of docetaxel: preparation, in vitro and in vivo evaluation" </p> <p style="text-align: center;"> EUFEPS Networks Panel EPRIN, Ana Alfirevic QbD PAT, Jukka Rantanen Veterinary Sciences, Ivo Schmerold Systems Pharmacology, Meindert Danhof Nanomedicine, Erem Bilensoy BABP, Werner Weitschies </p>	
19.00-21.00	Opening ceremony and welcome reception Venue: University Rectorate Building under the patronage of Rector of University of Athens	

Friday, 25 May 2017

09.00- 09.30	PL-4 Leslie Benet, US “Calculating extraction ratios and predicting IVIVE: The unrecognized assumptions”	
09.30-10.00	PL-5 The Douwe Breimer Lecture, Per Artursson, Sweden “Intracellular drug bioavailability: a new predictor of transport and metabolism dependent drug disposition and intracellular target engagement.”	
10.00-10.30	Coffee break and Poster Session-2	
Parallel sessions II		
	Performance of dosage forms in the body and impact on drug absorption	Nanomedicines: Challenges on the road <i>Organized by EUFEPS Nanomedicine Network</i>
10.30-11.00	IL-6 Werner Weitschies, Germany “GI physiology vs. formulation technology: who is in the driving seat?”	IL-8 Richard Harvey, Germany “Antimicrobial nanomedicines for pulmonary delivery”
11.00-11.30	IL-7 Konstantina Soulele, Greece “Population pharmacokinetics in inhaled drugs”	IL-9 Maria Blanco Prieto, Spain “Nanomedicines in paediatric cancer”
11.30-12.00	OP-3, Nasir Idkaidek, Jordan The use of saliva instead of plasma as a surrogate for drug bioavailability and bioequivalence studies in humans” OP-4, Hristos Glavinas, Hungary Improved bioavailability of a novel abiraterone acetate formulation is driven by immediate transfer of the drug from amorphous nanoparticles to bile micelles followed by its rapid conversion to abiraterone in the intestine”	OP-5, Bruno Sarmiento, Portugal “Engineered albumin variants are promising surface functional moieties to surpass the intestinal barrier for insulin-loaded nanoparticles” OP-6, Sila Gülbağ, Turkey, “Top down production of cyclosporine A nanosuspensions for oral delivery: formulation design and characterization”
12.00-13.30	Lunch break	
Parallel sessions III		
	Drug absorption, dissolution and in-silico modelling – towards prediction paradise?	Manufacturing of future medicines
13.30-14.00	IL-10 Maria Vertzoni, Greece “Advances in biorelevant oral drug product performance testing”	IL-13 Karl-Heinz Seyfang, Germany “Dosing and process control technologies to cover the wide variety of dry powder inhalers”
14.00-14.30	IL-11 Christos Reppas, Greece “Drug absorption from the lower intestine? “	IL-14 Umay Şaplakoğlu, US “Continuous manufacturing of biotech drugs”
14.30-15.00	IL-12 Hartmut Derendorf, US “Modeling and simulation to streamline dose optimization on earth and in space“	IL-15 Sarah Barthold , Germany “Drug delivery in the pediatric and geriatric patient population – Advantages of multiparticulates“
15.00-15.30	Coffee break and Poster Session-3	
Parallel sessions IV		
	Information on drug absorption in regulatory processes: nice-to-know vs. need-to-know	Nanomedicines: from lab to market <i>Organized by EUFEPS Nanomedicine Network</i>
15.30 -16.00	IL-16 Annette Bauer-Brandl, Denmark “In Vitro performance ranking of bioavailability-enhancing oral formulations: Recent advances“	IL-17 Caroline Lemarchand, France “CMC experience in clinical development of nanomedicine”
16.00-16.30	OP-7 Korbinian Löbman, Denmark “In situ amorphization using microwaves. A Potential way to amorphize drug within the final dosage form” OP-8 Gaia Colombo, Italy “Brain and plasma pharmacokinetics of flurbiprofen after nasal powder administration”	IL-18 Rana Sanyal, Turkey “From Synthesis toward Clinical: An experience in Nanomedicine“
16.30-17.00	OP-9 Matej Novak, Czechia “Development of FDM 3D printing as a formulation method for drugs with low bioavailability” OP-10 Sven Stegemann, Austria, “Medicine development for the older and clinically complex patients- closing the gaps to patient centric product design	OP-16 Gamze Varan, Turkey “Evaluation of the apoptotic action mechanism cholesterol targeted amphiphilic cyclodextrin nanoparticles OP-19 Petra Salamunova, Czechia “Research of glucan particles as potential carriers of diplacone for treatment of idiopathic inflammation diseases”
Parallel sessions V		
	EUFEPS Network Pharmacogenetics Research and Implementation (EPRIN)	Biotech and Biosimilars: What is the next step for the future
17.00-17.30	IL-20 Magnus-Ingelman Sundberg, Sweden “Challenges of rare genetic variants in prediction of drug response and adverse drug reactions“	IL-22 Thomas Felix, US Biosimilars: Clinical Relevance of Analytical Structure-Function Studies”
17.30-18.00	IL-21 Andrew Owen, UK “Towards stratified medicine approaches using nanotechnology-based drug delivery systems: A focus on infectious diseases“	IL-23 Ulrike Konrad, Germany “CMC Considerations for Biosimilar Drug Development”
18.00-18.30	OP-11 Kate Bloch, UK “Sequencing in hypersensitivity reactions” OP-12 Paula Perez Pardo, Netherlands “Effects of combined intervention with levodopa and a neurorestorative diet in a mouse model of Parkinson’s disease”	IL-24 Arnold Vulto, Netherlands “Clinical evaluation and interchangeability of biotech products from clinical pharmacist’s point of view”

Saturday, 26 May 2017

09.30 - 10.00	PL-5 Sir Munir Pirmohamed, UK, "Personalized medicine in order to optimize drug efficacy and minimize toxicity"		
10.00-10.30	Coffee break and Poster Session 4		
Parallel sessions VI			
	Enhanced Drug Delivery Approaches	Biotech Drugs and Biosimilars Development	Nanotechnology in Health Sciences <i>Organized by</i> <i>EUFEPS Nanomedicine Network</i>
10.30 -11.00	OP-13 Carla Caramella, Italy "Combination products: balancing innovation and technological innovation" OP-14 Flavia Laffleur, Austria "Novel polymeric dosage form for crossing the nail barrier"	IL-25 Despoina Sanoudou, Greece "Genomics and Molecular Biology in drug development and assessment"	IL-28 Devrim Gözüaçık, Turkey "From Cellular Stress Studies to Diagnosis of Diseases using Biochips and Nano Tools"
11.00 -11.30	OP-15 Meritxell Teixido, Spain "Blood-brain barrier shuttle peptides: an emerging tool for brain delivery" OP-25 Seda Rençber, Turkey "Investigations On The Mucoadhesive Hot-Melt Extruded Implants For Treatment Of Vaginal Candidiasis"	IL-26 İrem Yenice, Turkey "Development of a biosimilar monoclonal antibody drug"	OP-20 Silvia Franze, Italy "Novel approaches to prevent drug leakage from deformable liposomes" OP-21 Ayşe Ercan, Turkey "Genomic and metabolomics studies on polycationic amphiphilic cycloextrin nanoparticles on HEPG2 cell line"
11.30-12.00	OP-17 Fakhru Ahsan, US "Multi purpose filaments of HPMC for 3D printing of medications with tailored drug release and timed absorption"	IL-27 Amir Farschi, Iran "MAb development, being fast & furious"	IL-29 Rogerio Gaspar, Portugal, "Nanomedicine and the challenges for integrative healthcare"
12.00-13.30	Lunch break		
Parallel sessions VII			
	EUFEPS Network Systems Pharmacology	New drugs in Oncology <i>German Pharmaceutical Society DPhG</i>	
13.30-14.00	IL-30 Robert Bies, US "On the dilemma of irreproducibility: Inherent or statistical?"	IL-33 Stefan Laufer, Germany "EGFR Triple Mutant: Recent Set-Backs and New Hopes in Fighting Mutant Non-Small Cell Lung Cancer"	OP-23 Angela Fabiano, Italy "Mucoadhesive nanoparticles and oral bioavailability" OP-24 Adryana Clementino, Italy "Mucoadhesion and permeation enhancing of different nanoparticles in excised nasal tissues: a comparative study"
14.00-14.30	IL-31 Aris Dokoumetzidis, Greece "Order reduction of large PBPK and QSP models"	IL-34 Kristian Strømgaard, Sweden "Targeting syntenin and inhibition of cancer"	
14.30-15.00	IL-32 Lars Kuepfer, Germany "Simulating cellular drug responses within a whole-body"	IL-35 Romano Silvestri, Italy "New anti-cancer agents through an interaction with tubulin"	
15.00-15.30	<p align="center">Awards and Closing ceremony</p> <p align="center">EJPS Best Paper Award 2017 EUFEPS 2018 Best Poster & Oral Award EUFEPS WIPS Awards EUFEPS Presidential Distinction Awards</p>		